Ovoca Bio plc
("Ovoca" or the "Company")
Board Changes
Ovoca Bio, a biopharmaceutical company with a focus on women's health, is pleased to announce the appointment of Anastasia Levashova as an Independent Non-Executive Director with immediate effect. It also announces that Leonid Skoptsov will retire from the Board with immediate effect.
Ms. Levashova is a Portfolio Manager at Blackfriars Asset Management, a London, UK based fund management boutique specializing in equities investment within global emerging and frontier markets. She has over 20 years' experience in investing across emerging markets working in New York, London and Moscow in Bank of America Merrill Lynch, BNP Paribas and Citibank. Ms. Levashova holds a PhD from Moscow Lomonosov State University in International Relations and an MA in International Finance from Columbia University.
Ovoca Chief Executive & Interim Chairman, Kirill Golovanov, commented:
"We are delighted to welcome Anastasia to the board. She has deep asset management and investment banking experience and has long-standing relationships with financial institutions, private investors and other capital market participants. I look forward to working with Anastasia as we continue our development activities for our lead asset, orenetide, in major global markets.
In addition, I want to publicly thank Leonid for his years of service and dedication to improving our business and helping grow shareholder value. He provided strategic leadership in the early days of the Company's establishment and has continued to give invaluable guidance to the Board and our team through the whole of his service."
Additional Information:
Anastasia Levashova (aged 45 years) does not hold any ordinary shares or share options in the Company.
| Current Directorships | Past Directorships |
| Director, My Wealth World Ltd. | Director, Globaltruck Ltd. Director, Ashanti Gold Corp. |
The Company confirms that there is no other information that is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies and Rule 5.22 (b) of Chapter 5: Additional Rules for the Euronext Growth Market operated by Euronext Dublin.
For further information, contact:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
info@ovocabio.com
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
John Frain / Daragh O'Reilly
Tel: +353 1 679 6363
Consilium Strategic Communications
Chris Gardner, Chris Welsh
ovocabio@consilium-comms.com
Tel: +44 (0)20 3709 5700
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
